Amarin Extends Vazkepa Patent Protection in Europe

By Bobby Samwell • Wednesday, April 03 15:19 • Permanent Link

Amarin Corporation Plc (NASDAQ:AMRN) has announced an extension of its intellectual property protection for Vazkepa® (icosapent ethyl) in Europe, with a new patent granted by the European Patent Office (EPO) that will extend Vazkepa exclusivity eight additional years into 2039. This decision provides an extended and strengthened exclusivity position for Vazkepa within the company’s European market.

The new patent, with a grant date of April 24, 2024, covers Vazkepa in Europe until April 2039 and is based on the pivotal REDUCE-IT cardiovascular outcomes trial. Additionally, in November 2023, Amarin successfully defended a separate patent containing claims covering Vazkepa in Europe from third-party opposition. This patent, which expires in June 2033, contains claims for reducing the risk of cardiovascular death and coronary revascularization based on the REDUCE-IT trial protocol.

The successful outcomes reinforce Amarin’s existing Vazkepa European exclusivity, which comprises legacy patent exclusivity arising from the anchor study that received extensions via supplemental protection certificates (SPCs) until June 2035, layered upon Amarin’s regulatory exclusivity extending until March 2031. Collectively, these multiple layers of patent and regulatory protection provide a robust, multi-layered exclusivity position for Vazkepa within the European market into 2039.

This extension of intellectual property protection is expected to enhance the potential impact of Vazkepa for patients and the growth potential for Vazkepa across the continent. Patrick Holt, President & CEO of Amarin, emphasized the company's commitment to rigorously defending its IP rights and exploring possibilities to strengthen Amarin’s patents and patent families around the world.

Amarin Corporation Plc is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management, committed to increasing the scientific understanding of cardiovascular risk and advancing the treatment of that risk for patients worldwide.

This development represents a significant milestone for Amarin as it secures an extended period of exclusivity for Vazkepa in the European market, providing a strong foundation for the company's continued growth and impact in the cardiovascular disease management space. Today the company's shares have moved 6.1% to a price of $1.05. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.